

IN THE CLAIMS

1. (Currently Amended) A method for modulating the expression of a genetic sequence wherein said sequence comprises an ORF having an RTG or RUG wherein R is A or G corresponding to an authentic translation site of said ORF and a nucleotide sequence 5' of said authentic translation start site, said method comprising introducing ~~or removing~~ one or more ~~RTG or RUG~~ATG triplets in said 5' nucleotide sequence upstream of said authentic translation initiation site such that upon expression of said genetic sequence, there is a ~~respective decrease or increase~~ in the level of expression.
2. (Withdrawn) The method of Claim 96 wherein the expression is increased by the removal of one or more RTG or RUG triplets, wherein R is A or G in the 5' nucleotide sequence upstream of the authentic translation initiation site.
- 3-5. (Canceled)
6. (Withdrawn) The method of Claim 4 wherein the triplet is AUG.
7. (Currently Amended) The method of ~~any one of~~ Claims 1 ~~to 3~~ or 96 further comprising introducing or removing one or more termination signals in the 5' nucleotide sequence, the coding sequence or downstream of the authentic translation initiation site and/or in a 3' region to create or destroy a pseudo-ORF.
- 8-21. (Canceled)
22. (Withdrawn) A method for facilitating increased or elevated expression of a genetic sequence wherein said sequence comprises an ORF having an RTG or RUG wherein R is A or G corresponding to an authentic translation initiation site of said ORF and a nucleotide sequence 5' of said authentic translation initiation site, said method comprising removing one or more RTG or RUG triplets in said 5' nucleotide sequence upstream of said authentic translation initiation site such that upon expression of said genetic sequence, there is an increase in the level of

expression relative to expression of the genetic sequence in the absence of removal of any RTG or RUG triplet.

23. (Withdrawn) The method of Claim 97 wherein the triplet removed from the nucleotide sequence 5' of the authentic translation initiation site is ATG.

24. (Withdrawn) The method of Claim 97 wherein the triplet removed from the nucleotide sequence 5' of the authentic translation initiation site is AUG.

25. (Withdrawn) The method of any one of Claims 22 to 24 or 97 further comprising introducing or removing one or more termination signals in the 5' nucleotide sequence, the coding sequence or downstream of the authentic translation initiation site and/or in a 3' region to create or destroy a pseudo-ORF.

26-31. (Canceled)

32. (Currently Amended) A method for facilitating decreased or reduced expression of a genetic sequence wherein said sequence comprises an ORF having an RTG or RUG where R is A or G corresponding to an authentic translation initiation site of said ORF and a nucleotide sequence 5' of said authentic translation initiation site, said method comprising introducing or creating one or more ~~RTG or RUG~~ATG triplets in said 5' nucleotide sequence upstream of said authentic translation initiation site such that upon expression of said genetic sequence there is a decrease in the level of expression relative to expression of the genetic sequence in the absence of introducing ~~or removing~~ any ~~RTG or RUG~~ATG triplets.

33. (Withdrawn) The method of Claim 98 wherein the triplet removed from the nucleotide sequence 5' of the authentic translation initiation site is ATG.

34. (Withdrawn) The method of Claim 32 wherein the triplet removed from the nucleotide sequence 5' of the authentic translation initiation site is AUG.

35. (Currently Amended) The method of Claims 32 to 34 or 98 further comprising introducing or removing one or more termination signals in the 5' nucleotide sequence, the coding sequence or downstream of the authentic translation initiation site and/or in a 3' region to create or destroy a pseudo-ORF.

36-41. (Canceled)

42. (Currently Amended) A method for modulating the expression of a genetic sequence wherein said sequence comprises an ORF having an RTG or RUG corresponding to an authentic translation initiation site and a nucleotide sequence 5' of said authentic translation start site comprising the sequence:-

$$\{n_1 n_2 \dots n_a\}_m [x_1 x_2 x_3]_n \{n_1^I n_2^I \dots n_b^I\}_o [y_1^I y_2^I y_3^I] \{x_1^I x_2^I x_3^I\}_p [n_1^{II} n_2^{II} \dots n_c^{II}]_q \{y_1^{II} y_2^{II} y_3^{II}\} \\ [x_1^{II} x_2^{II} x_3^{II}]_r \{n_1^{III} n_2^{III} \dots n_d^{III}\}_s [y_1^{III} y_2^{III} y_3^{III}] \text{RT/UG} [z_1 z_2 \dots z_n]_t$$

wherein:

RT/UG is the authentic translation initiation site and R is A or G;

n , n^I , n^{II} and n^{III} are nucleotides selected from A, T or U, C or G or I;

$\{n_1 n_2 \dots n_a\}_m$, $\{n_1^I n_2^I \dots n_b^I\}_o$, $\{n_1^{II} n_2^{II} \dots n_c^{II}\}_q$ and $\{n_1^{III} n_2^{III} \dots n_d^{III}\}_s$ represent

nucleotide sequences of a, b, c or d nucleotides in length and where each of n , n^I , n^{II} and n^{III} may be the same or different and its position is indicated by the subscript numeral 1, 2, ...;

$[z_1 z_2 \dots z_n]_t$ represents a translation termination signal within an authentic ORF but not in the same reading frame as said authentic ORF;

each of m, n, o, p, q, r or s may be the same or different and each is 0 or 1 or if there is a repeat or multiple repeats, from about 2 or about 10;

t is 0, 1 or >1;

each of $[x_1 x_2 x_3]_n$, $[x_1^I x_2^I x_3^I]_p$ and $[x_1^{II} x_2^{II} x_3^{II}]_r$ is selected from the triplet RTG, RUG, RYG, RTY^I, RY^{II}G, RUY^{III}, ATG, GTG, AUG and GUG where R is A or G, and each of Y, Y^I, Y^{II} and Y^{III} may be the same or different and each is a nucleotide with the proviso that Y is not T, Y^I is not G, Y^{II} is not U and Y^{III} is not G;

each of $[y_1^I y_2^I y_3^I]$, $[y_1^{II} y_2^{II} y_3^{II}]$, $\{y_1^{II} y_2^{II} y_3^{II}\}$ and $[y_1^{III} y_2^{III} y_3^{III}]$ represents a translation termination signal; and

said method comprising altering the nucleotide triplets $[x_1 x_2 x_3]_n$, $[x_1^I x_2^I x_3^I]_p$ and/or $[x_1^{II} x_2^{II} x_3^{II}]_r$ to introduce ~~or remove~~ an RTG ~~or RUG~~ATG to thereby ~~respectively decrease or increase~~ the level of expression of said genetic sequence.

43. (Currently Amended) The method of Claim 42 wherein the genetic sequence is DNA.

44. (Withdrawn) The method of Claim 42 wherein the genetic sequence is RNA.

45. (Currently Amended) The method of Claim 42, or 43, ~~or 44~~ wherein the nucleotide sequence 5' of the authentic translation initiation site is:-

$$n_x n_{x+i} \dots n_{x+z}$$

wherein:

n_x is the first nucleotide in a leader sequence;

x is 1 or >1 (e.g. 100, 1000, 10,000 or greater);

i is 1;

z is an integer from 1 to 10;

n_{x+z} is the last nucleotide of the 5' leader sequence prior to the translation initiation

site;

wherein each n may be the same or different and each is A, C, G, U or T

and wherein a numerical value (N_v) is assigned to a genetic element such that if:-

n_{x+i} = n , as defined above;

n_{x+i+1} = A;

n_{x+i+2} = T or U; and

n_{x+i+3} = G

then the N_v is 1;

when

n_{x+i} = n , as defined above;

n_{x+i+1} = G;

$$\begin{aligned} n_{x+i+2} &= \text{T or U; and} \\ n_{x+i+3} &= \text{G} \end{aligned}$$

then the N_V is 0.3;

and when:-

$$\begin{aligned} n_{x+i} &= \text{n as defined above;} \\ n_{x+i+1} &= \text{C or G;} \\ n_{x+i+2} &= \text{T or C or G; and} \\ n_{x+i+3} &= \text{A, T or C} \end{aligned}$$

then the N_V is 0;

such that the level of expression (E_L) of a nucleotide sequence operably linked at its 5' end to $n_x n_{x+1} \dots n_{x+z}$ is inversely functionally associated (*) to the sum of N_V determined from the nucleotide sequence $n_x n_{x+1} \dots n_{x+z}$ such that

$$E_L * \frac{1}{\sum N_V}.$$

46. (Currently Amended) The method of Claim 45 wherein the nucleotide sequence 5' of the authentic translation initiation site is ~~derived from the~~ a *GLII* gene leader sequence, or fragment thereof.

47. (Currently Amended) The method of Claim 46 wherein the *GLII* gene leader sequence is ~~derived from a murine animal and~~ comprises the nucleotide sequence set forth in SEQ ID NO:1 or a nucleotide sequence having at least 60% similarity thereto or a nucleotide sequence capable of hybridizing to SEQ ID NO:1 or its complementary form under ~~low~~ stringency conditions comprising 2 x SSC buffer, 0.15% w/v SDS at 42°C.

48. (Currently Amended) The method of Claim 46 wherein the *GLII* gene leader sequence is ~~derived from a murine animal and~~ comprises the nucleotide sequence set forth in SEQ ID NO:1 or a nucleotide sequence having at least 60% similarity thereto or a nucleotide sequence capable

of hybridizing to SEQ ID NO:2 or its complementary form under ~~low~~ stringency conditions comprising 2 x SSC buffer, 0.15% w/v SDS at 42°C.

49. (Currently Amended) The method of Claim 46 wherein the *GLII* gene leader sequence is ~~derived from a murine animal and~~ comprises the nucleotide sequence set forth in SEQ ID NO:1 or a nucleotide sequence having at least 60% similarity thereto or a nucleotide sequence capable of hybridizing to SEQ ID NO:3 or its complementary form under ~~low~~ stringency conditions comprising 2 x SSC buffer, 0.15% w/v SDS at 42°C.

50. (Currently Amended) The method of Claim 46 wherein the *GLII* gene leader sequence is ~~derived from a human and~~ comprises the nucleotide sequence set forth in SEQ ID NO:1 or a nucleotide sequence having at least 60% similarity thereto or a nucleotide sequence capable of hybridizing to SEQ ID NO:4 or its complementary form under ~~low~~ stringency conditions comprising 2 x SSC buffer, 0.15% w/v SDS at 42°C.

51. (Currently Amended) The method of Claim 46 wherein the *GLII* gene leader sequence is ~~derived from a human~~ comprises the nucleotide sequence set forth in SEQ ID NO:1 or a nucleotide sequence having at least 60% similarity thereto or a nucleotide sequence capable of hybridizing to SEQ ID NO:5 or its complementary form under ~~low~~ stringency conditions comprising 2 x SSC buffer, 0.15% w/v SDS at 42°C.

52. (Withdrawn) An isolated nucleic acid molecule for use in modulating the expression of a genetic sequence wherein said genetic sequence comprises a coding region comprising a translation initiation site and optionally a 5' leader sequence such that said nucleotide sequence comprising a predetermined number of RTG or RUG triplets such that upon operable linkage to the 5' end of the genetic sequence, the level of expression of said genetic sequence is determined by the number of RTG/RUG triplets.

53. (Withdrawn) The nucleic acid molecule of Claim 99 wherein the triplet in the 5' leader sequence is ATG.

54. (Withdrawn) The nucleic acid molecule of Claim 99 wherein the triplet in the 5' leader sequence is AUG.

55. (Withdrawn) The nucleic acid molecule of Claim 53 or 54 wherein the nucleotide sequence 5' of the authentic translation initiation site is derived from the *GLII* gene leader sequence.

56. (Withdrawn) The nucleic acid molecule of Claim 55 wherein the *GLII* gene leader sequence is derived from a murine animal and comprises the nucleotide sequence set forth in SEQ ID NO:1 or a nucleotide sequence having at least 60% similarity thereto or a nucleotide sequence capable of hybridizing to SEQ ID NO:1 or its complementary form under low stringency conditions.

57. (Withdrawn) The nucleic acid molecule of Claim 55 wherein the *GLII* gene leader sequence is derived from a murine animal and comprises the nucleotide sequence set forth in SEQ ID NO:1 or a nucleotide sequence having at least 60% similarity thereto or a nucleotide sequence capable of hybridizing to SEQ ID NO:2 or its complementary form under low stringency conditions.

58. (Withdrawn) The nucleic acid molecule of Claim 55 wherein the *GLII* gene leader sequence is derived from a murine animal and comprises the nucleotide sequence set forth in SEQ ID NO:1 or a nucleotide sequence having at least 60% similarity thereto or a nucleotide sequence capable of hybridizing to SEQ ID NO:3 or its complementary form under low stringency conditions.

59. (Withdrawn) The nucleic acid molecule of Claim 55 wherein the *GLII* gene leader sequence is derived from a human and comprises the nucleotide sequence set forth in SEQ ID NO:1 or a nucleotide sequence having at least 60% similarity thereto or a nucleotide sequence capable of hybridizing to SEQ ID NO:4 or its complementary form under low stringency conditions.

60. (Withdrawn) The nucleic acid molecule of Claim 55 wherein the *GLII* gene leader sequence is derived from a human comprises the nucleotide sequence set forth in SEQ ID NO:1 or a nucleotide sequence having at least 60% similarity thereto or a nucleotide sequence capable of hybridizing to SEQ ID NO:5 or its complementary form under low stringency conditions.

61. (Withdrawn) A genetic construct comprising a promoter linked to a genetic element and one or more restriction endonuclease sites to facilitate insertion of a nucleotide sequence to be expressed by said promoter wherein said genetic element comprises a predetermined number of pseudo-translation initiation RTG/RUG triplets wherein R is A or G such that the level of expression of said nucleotide sequence by said promoter is inversely functionally associated with the number of RTG/RUG triplets in said genetic element.

62. (Withdrawn) The genetic construct of Claim 61 wherein the genetic element comprises the nucleotide sequence:-

$$n_x n_{x+i} \dots n_{x+z}$$

wherein:

n_x is the first nucleotide in a leader sequence;

x is 1 or >1 (e.g. 100, 1000, 10,000 or greater);

i is 1;

z is an integer from 1 to 10;

n_{x+z} is the last nucleotide of the 5' leader sequence prior to the translation initiation site;

wherein each n may be the same or different and each is A, C, G, U or T or I

and wherein a numerical value (N_v) is assigned to a genetic element such that if:-

n_{x+i} = n , as defined above;

n_{x+i+1} = A;

n_{x+i+2} = T or U; and

n_{x+i+3} = G

then the N_v is 1;

when

n_{x+i} = n , as defined above;

$$\begin{aligned}n_{x+i+1} &= G; \\n_{x+i+2} &= T \text{ or } U; \text{ and} \\n_{x+i+3} &= G\end{aligned}$$

then the N_V is 0.3;

and when:-

$$\begin{aligned}n_{x+i} &= n \text{ as defined above;} \\n_{x+i+1} &= C \text{ or } G; \\n_{x+i+2} &= T \text{ or } C \text{ or } G; \text{ and} \\n_{x+i+3} &= A, T \text{ or } C\end{aligned}$$

then the N_V is 0;

such that the level of expression (E_L) of a nucleotide sequence operably linked at its 5' end to $n_x n_{x+1} \dots n_{x+z}$ is inversely functionally associated (*) to the sum of N_V determined from the nucleotide sequence $n_x n_{x+1} \dots n_{x+z}$ such that

$$E_L * \frac{1}{\sum N_V}.$$

63. (Withdrawn) The genetic construct molecule of Claim 62 wherein the genetic element comprises 5' leader sequence from the *GLII* gene.

64. (Withdrawn) The genetic construct of Claim 63 wherein the *GLII* gene leader sequence is derived from a murine animal and comprises the nucleotide sequence set forth in SEQ ID NO:1 or a nucleotide sequence having at least 60% similarity thereto or a nucleotide sequence capable of hybridizing to SEQ ID NO:1 or its complementary form under low stringency conditions.

65. (Withdrawn) The genetic construct of Claim 63 wherein the *GLII* gene leader sequence is derived from a murine animal and comprises the nucleotide sequence set forth in SEQ ID NO:1 or a nucleotide sequence having at least 60% similarity thereto or a nucleotide sequence

capable of hybridizing to SEQ ID NO:2 or its complementary form under low stringency conditions.

66. (Withdrawn) The genetic construct of Claim 63 wherein the *GLII* gene leader sequence is derived from a murine animal and comprises the nucleotide sequence set forth in SEQ ID NO:1 or a nucleotide sequence having at least 60% similarity thereto or a nucleotide sequence capable of hybridizing to SEQ ID NO:3 or its complementary form under low stringency conditions.

67. (Withdrawn) The genetic construct of Claim 63 wherein the *GLII* gene leader sequence is derived from a human and comprises the nucleotide sequence set forth in SEQ ID NO:1 or a nucleotide sequence having at least 60% similarity thereto or a nucleotide sequence capable of hybridizing to SEQ ID NO:4 or its complementary form under low stringency conditions.

68. (Withdrawn) The genetic construct of Claim 63 wherein the *GLII* gene leader sequence is derived from a human comprises the nucleotide sequence set forth in SEQ ID NO:1 or a nucleotide sequence having at least 60% similarity thereto or a nucleotide sequence capable of hybridizing to SEQ ID NO:5 or its complementary form under low stringency conditions.

69. (Withdrawn) A method for modulating expression of a genetic sequence which genetic sequence comprises an ORF with an authentic translation initiation site and further comprising a sequence upstream of said authentication translation initiation site where said method comprises introducing, creating or removing one or more pseudo-translation initiation triplets having the structure RWG wherein R is A or G and W is T or U in combination with introducing, creating or removing a Kozac or Kozac-like sequence proximal to said RWG such that the number of RWG triplets and Kozac or Kozac-like sequences is inversely functionally associated with expression of said genetic sequence.

70. (Withdrawn) The method according to Claim 69 wherein the pseudo-translation initiation triplet is ATG.

71. (Withdrawn) The method according to Claim 69 wherein the pseudo-translation initiation triplet is GTG.

72. (Withdrawn) The method according to Claim 69 wherein the pseudo-translation initiation triplet is AUG.

73. (Withdrawn) The method according to Claim 69 wherein the pseudo-translation initiation triplet is GUG.

74. (Withdrawn) The method according to Claim 69 wherein the introduction, creation or removal of a pseudo-translation initiation triplet creates the sequence:-

RnCCRWGn (SEQ ID NO:11)

wherein:-

R is A or G;

n is any nucleotide; and

W is T or U.

75. (Currently Amended) A method for modulating the expression of a genetic sequence in a plant cell wherein said sequence comprises an ORF having an RTG or RUG wherein R is A or G corresponding to an authentic translation site of said ORF and a nucleotide sequence 5' of said authentic translation start site, said method comprising introducing ~~or removing~~ one or more ~~RTG or RUG~~ATG triplets in said 5' nucleotide sequence upstream of said authentic translation initiation site such that upon expression of said genetic sequence, there is a ~~respective~~ decrease ~~or increase~~ in the level of expression.

76. (Withdrawn) The method of Claim 75 wherein the expression is increased by the removal of one or more RTG or RUG triplets, wherein R is A or G in the 5' nucleotide sequence upstream of the authentic translation initiation site.

77-79. (Canceled)

80. (Withdrawn) The method of Claim 78 wherein the triplet is AUG.
81. (Currently Amended) The method of ~~any one of Claims 76 to 80~~Claim 75 further comprising introducing or removing one or more termination signals in the 5' nucleotide sequence, the coding sequence or downstream of the authentic translation initiation site and/or in a 3' region to create or destroy a pseudo-ORF.
82. (Currently Amended) The method of Claim 75 or 81 wherein the plant cell is from a cereal crop, a vegetable plant, a fruiting plant, a flowering plant or cotton or tobacco.
83. (Previously Presented) The method of Claim 82 wherein the plant cell is from cotton.
84. (Previously Presented) The method of Claim 82 wherein the plant cell is from a cereal crop.
85. (Previously Presented) The method of Claim 82 wherein the target sequence whose expression is modulated confers resistance to a herbicide.
86. (Previously Presented) The method of Claim 82 wherein the target sequence whose expression is modulated confers resistance to a pesticide.
87. (Currently Amended) A method for modulating the expression of a genetic sequence in an animal cell wherein said sequence comprises an ORF having an RTG or RUG wherein R is A or G corresponding to an authentic translation site of said ORF and a nucleotide sequence 5' of said authentic translation start site, said method comprising introducing ~~or removing~~ one or more ~~RTG or RUG~~ATG triplets in said 5' nucleotide sequence upstream of said authentic translation initiation site such that upon expression of said genetic sequence, there is a ~~respective~~ decrease ~~or increase~~ in the level of expression.

88. (Withdrawn) The method of Claim 87 wherein the expression is increased by the removal of one or more RTG or RUG triplets, wherein R is A or G in the 5' nucleotide sequence upstream of the authentic translation initiation site.

89-91. (Canceled)

92. (Withdrawn) The method of Claim 90 wherein the triplet is AUG.

93. (Withdrawn) The method of any one of Claims 88 further comprising introducing or removing one or more termination signals in the 5' nucleotide sequence, the coding sequence or downstream of the authentic translation initiation site and/or in a 3' region to create or destroy a pseudo-ORF.

94. (Currently Amended) The method of Claim 87 ~~or 93~~ wherein the animal cell is a mammalian cell.

95. (Currently Amended) The method of Claim 87 ~~or 93~~ wherein the animal cell is a human cell.

96. (Currently Amended) The method of Claim 1 wherein the nucleotide sequence 5' of the authentic translation initiation site comprises the sequence:

$$\{n_1 n_2 \dots n_a\}_m [x_1 x_2 x_3]_n \{n_1^I n_2^I \dots n_b^I\}_o [y_1^I y_2^I y_3^I] \{x_1^I x_2^I x_3^I\}_p [n_1^{II} n_2^{II} \dots n_c^{II}]_q \{y_1^{II} y_2^{II} y_3^{II}\} \\ [x_1^{II} x_2^{II} x_3^{II}]_r \{n_1^{III} n_2^{III} \dots n_d^{III}\}_s [y_1^{III} y_2^{III} y_3^{III}] \text{RT/UG} [z_1 z_2 \dots z_n]_t$$

wherein:

RT/UG is the authentic translation initiation site and R is A or G;

n , n^I , n^{II} and n^{III} are nucleotides selected from A, T or U, C or G or I;

$\{n_1 n_2 \dots n_a\}_m$, $\{n_1^I n_2^I \dots n_b^I\}_o$, $\{n_1^{II} n_2^{II} \dots n_c^{II}\}_q$ and $\{n_1^{III} n_2^{III} \dots n_d^{III}\}_s$ represent

nucleotide sequences of a, b, c or d nucleotides in length and where each of n , n^I , n^{II} and n^{III} may be the same or different and its position is indicated by the subscript numeral 1, 2, ...;

$[z_1 z_2 \dots z_n]$ represents a translation termination signal within an authentic ORF but not in the same reading frame as said authentic ORF;

each of m, n, o, p, q, r or s may be the same or different and each is 0 or 1 or if there is a repeat or multiple repeats, from about 2 or about 10;

t is 0, 1 or >1;

each of $[x_1 x_2 x_3]_n$, $[x_1^I x_2^I x_3^I]_p$ and $[x_1^{II} x_2^{II} x_3^{II}]_r$ is selected from the triplet RTG, RUG, RYG, RTY^I, RY^{II}G, RUY^{III}, ATG, GTG, AUG and GUG where R is A or G, and each of Y, Y^I, Y^{II} and Y^{III} may be the same or different and each is a nucleotide with the proviso that Y is not T, Y^I is not G, Y^{II} is not U and Y^{III} is not G;

each of $[y_1^I y_2^I y_3^I]$, $[y_1^{II} y_2^{II} y_3^{II}]$, $\{y_1^{II} y_2^{II} y_3^{II}\}$ and $[y_1^{III} y_2^{III} y_3^{III}]$ represents a translation termination signal; and

said method comprising altering the nucleotide triplets $[x_1 x_2 x_3]_n$, $[x_1^I x_2^I x_3^I]_p$ and/or $[x_1^{II} x_2^{II} x_3^{II}]_r$ to introduce ~~or remove an RTG or RUG to an~~ ATG and thereby respectively decrease ~~or increase~~ the level of expression of said genetic sequence.

97. (Withdrawn) The method of Claim 22 wherein the nucleotide sequence 5' of the authentic translation initiation site comprises the sequence:

$$\{n_1 n_2 \dots n_a\}_m [x_1 x_2 x_3]_n \{n_1^I n_2^I \dots n_b^I\}_o [y_1^I y_2^I y_3^I] \{x_1^I x_2^I x_3^I\}_p [n_1^{II} n_2^{II} \dots n_c^{II}]_q \{y_1^{II} y_2^{II} y_3^{II}\} \\ [x_1^{II} x_2^{II} x_3^{II}]_r \{n_1^{III} n_2^{III} \dots n_d^{III}\}_s [y_1^{III} y_2^{III} y_3^{III}] \text{RT/UG} [z_1 z_2 \dots z_n]_t$$

wherein:

RT/UG is the authentic translation initiation site and R is A or G;

n, n^I, n^{II} and n^{III} are nucleotides selected from A, T or U, C or G or I;

$\{n_1 n_2 \dots n_a\}_m$, $\{n_1^I n_2^I \dots n_b^I\}_o$, $\{n_1^{II} n_2^{II} \dots n_c^{II}\}_q$ and $\{n_1^{III} n_2^{III} \dots n_d^{III}\}_s$ represent

nucleotide sequences of a, b, c or d nucleotides in length and where each of n, n^I, n^{II} and n^{III} may be the same or different and its position is indicated by the subscript numeral 1, 2, ...;

$[z_1 z_2 \dots z_n]$ represents a translation termination signal within an authentic ORF but not in the same reading frame as said authentic ORF;

each of m, n, o, p, q, r or s may be the same or different and each is 0 or 1 or if there is a repeat or multiple repeats, from about 2 or about 10;

t is 0,1 or >1;

each of $[x_1x_2x_3]_n$, $[x_1^Ix_2^Ix_3^I]_p$ and $[x_1^{II}x_2^{II}x_3^{II}]_r$ is selected from the triplet RTG, RUG, RYG, RTY^I, RY^{II}G, RUY^{III}, ATG, GTG, AUG and GUG where R is A or G, and each of Y, Y^I, Y^{II} and Y^{III} may be the same or different and each is a nucleotide with the proviso that Y is not T, Y^I is not G, Y^{II} is not U and Y^{III} is not G;

each of $[y_1^Iy_2^Iy_3^I]$, $[y_1^{II}y_2^{II}y_3^{II}]$ and $[y_1^{III}y_2^{III}y_3^{III}]$ represents a translation termination signal; and

said method comprising altering the nucleotide triplets $[x_1x_2x_3]_n$, $[x_1^Ix_2^Ix_3^I]_p$ and/or $[x_1^{II}x_2^{II}x_3^{II}]_r$ to introduce or remove an RTG or RUG to thereby respectively decrease or increase the level of expression of said genetic sequence.

98. (Currently Amended) The method of Claim 32 wherein the nucleotide sequence 5' of the authentic translation initiation site comprises the sequence:

$$\{n_1n_2 \dots n_a\}_m [x_1x_2x_3]_n \{n_1^In_2^I \dots n_b^I\}_o [y_1^Iy_2^Iy_3^I] \{x_1^Ix_2^Ix_3^I\}_p [n_1^{II}n_2^{II} \dots n_c^{II}]_q \{y_1^{II}y_2^{II}y_3^{II}\}$$

$$[x_1^{II}x_2^{II}x_3^{II}]_r \{n_1^{III}n_2^{III} \dots n_d^{III}\}_s [y_1^{III}y_2^{III}y_3^{III}] \text{RT/UG} [z_1z_2 \dots z_n]_t$$

wherein:

RT/UG is the authentic translation initiation site and R is A or G;

n, n^I, n^{II} and n^{III} are nucleotides selected from A, T or U, C or G or I;

$\{n_1n_2 \dots n_a\}_m$, $\{n_1^In_2^I \dots n_b^I\}_o$, $\{n_1^{II}n_2^{II} \dots n_c^{II}\}_q$ and $\{n_1^{III}n_2^{III} \dots n_d^{III}\}_s$ represent

nucleotide sequences of a, b, c or d nucleotides in length and where each of n, n^I, n^{II} and n^{III} may be the same or different and its position is indicated by the subscript numeral 1, 2, ...;

$[z_1z_2 \dots z_n]_t$ represents a translation termination signal within an authentic ORF but not in the same reading frame as said authentic ORF;

each of m, n, o, p, q, r or s may be the same or different and each is 0 or 1 or if there is a repeat or multiple repeats, from about 2 or about 10;

t is 0,1 or >1;

each of $[x_1x_2x_3]_n$, $[x_1^Ix_2^Ix_3^I]_p$ and $[x_1^{II}x_2^{II}x_3^{II}]_r$ is selected from the triplet RTG, RUG, RYG, RTY^I, RY^{II}G, RUY^{III}, ATG, GTG, AUG and GUG where R is A or G, and each of Y, Y^I, Y^{II} and Y^{III} may be the same or different and each is a nucleotide with the proviso that Y is not T, Y^I is not G, Y^{II} is not U and Y^{III} is not G;

each of $[y_1^Iy_2^Iy_3^I]$, $[y_1^{II}y_2^{II}y_3^{II}]$, $\{y_1^{II}y_2^{II}y_3^{II}\}$ and $[y_1^{III}y_2^{III}y_3^{III}]$ represents a translation termination signal; and

said method comprising altering the nucleotide triplets $[x_1x_2x_3]_n$, $[x_1^Ix_2^Ix_3^I]_p$ and/or $[x_1^{II}x_2^{II}x_3^{II}]_r$ to introduce or remove an RTG or RUGATG to thereby respectively decrease or increase the level of expression of said genetic sequence.

99. (Withdrawn) The nucleic acid molecule of Claim 52 wherein the nucleotide sequence 5' of the authentic translation initiation site comprises the sequence:

$$\{n_1n_2 \dots n_a\}_m [x_1x_2x_3]_n \{n_1^In_2^I \dots n_b^I\}_o [y_1^Iy_2^Iy_3^I] \{x_1^Ix_2^Ix_3^I\}_p [n_1^{II}n_2^{II} \dots n_c^{II}]_q \{y_1^{II}y_2^{II}y_3^{II}\} \\ [x_1^{II}x_2^{II}x_3^{II}]_r \{n_1^{III}n_2^{III} \dots n_d^{III}\}_s [y_1^{III}y_2^{III}y_3^{III}] \text{RT/UG} [z_1z_2 \dots z_n]_t$$

wherein:

RT/UG is the authentic translation initiation site and R is A or G;

n, n^I, n^{II} and n^{III} are nucleotides selected from A, T or U, C or G or I;

$\{n_1n_2 \dots n_a\}_m$, $\{n_1^In_2^I \dots n_b^I\}_o$, $\{n_1^{II}n_2^{II} \dots n_c^{II}\}_q$ and $\{n_1^{III}n_2^{III} \dots n_d^{III}\}_s$ represent

nucleotide sequences of a, b, c or d nucleotides in length and where each of n, n^I, n^{II} and n^{III} may be the same or different and its position is indicated by the subscript numeral 1, 2, ...;

$[z_1z_2 \dots z_n]_t$ represents a translation termination signal within an authentic ORF but not in the same reading frame as said authentic ORF;

each of m, n, o, p, q, r or s may be the same or different and each is 0 or 1 or if there is a repeat or multiple repeats, from about 2 or about 10;

t is 0, 1 or >1;

each of $[x_1x_2x_3]_n$, $[x_1^Ix_2^Ix_3^I]_p$ and $[x_1^{II}x_2^{II}x_3^{II}]_r$ is selected from the triplet RTG, RUG, RYG, RTY^I, RY^{II}G, RUY^{III}, ATG, GTG, AUG and GUG where R is A or G, and each of

Y, Y^I, Y^{II} and Y^{III} may be the same or different and each is a nucleotide with the proviso that Y is not T, Y^I is not G, Y^{II} is not U and Y^{III} is not G;

each of $[y_1^I y_2^I y_3^I]$, $[y_1^{II} y_2^{II} y_3^{II}]$ and $[y_1^{III} y_2^{III} y_3^{III}]$ represents a translation termination signal; and

said method comprising altering the nucleotide triplets $[x_1 x_2 x_3]_n$, $[x_1^I x_2^I x_3^I]_p$ and/or $[x_1^{II} x_2^{II} x_3^{II}]_r$ to introduce or remove an RTG or RUG to thereby respectively decrease or increase the level of expression of said genetic sequence.